Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo Study-Reference-Cited by-同舟云学术

Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo Study

Published:2004-09-17 Issue:40 Volume:43 Page:12931-12936
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Meggio Flavio¹,Pagano Mario A.¹,Moro Stefano¹,Zagotto Giuseppe¹,Ruzzene Maria¹,Sarno Stefania¹,Cozza Giorgio¹,Bain Jenny¹,Elliott Matthew¹,Deana Arianna Donella¹,Brunati Anna Maria¹,Pinna Lorenzo A.¹

Affiliation:

1. Dipartimento di Chimica Biologica, Istituto di Neuroscienze del CNR, and Dipartimento di Scienze Farmaceutiche, Università di Padova, Padova, Italy, and Medical Research Council Protein Phosphorylation Unit, University of Dundee, Dundee DD1 5EH, U.K.

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/bi048999g

Reference33 articles.

1. One‐thousand‐and‐one substrates of protein kinase CK2?

2. Guerra, B., and Issinger, O.G. (1999) Protein kinase CK2 and its role in cellular proliferation, development and pathology,Electrophoresis 20, 391−408

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serine/Threonine Protein Kinases as Attractive Targets for Anti-Cancer Drugs—An Innovative Approach to Ligand Tuning Using Combined Quantum Chemical Calculations, Molecular Docking, Molecular Dynamic Simulations, and Network-like Similarity Graphs;Molecules;2024-07-05

2. Design and Synthesis of Potent Anticancer Agents Using Coumarin‐Quinazolinone Based Scaffolds: Exploration of ADME Properties and Molecular Docking Studies;ChemistrySelect;2024-04-25

3. CK2 Inhibitors Targeting Inside and Outside the Catalytic Box;Kinases and Phosphatases;2024-03-26

4. Scoping Pleiotropy of CK2 in Musculoskeletal Disorders for a Novel Targeting Approach;Kinases and Phosphatases;2024-01-31

5. Casein kinase (CK) inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024